Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys

Leukemia and Lymphoma

Volumn 45, Issue 8, 2004, Pages 1647-1656

  Cohen, Kimberley A ^a   Liu, Tie Fu ^a   Cline, J Mark ^a   Wagner, Janice D ^a   Hall, Philip D ^b   Frankel, Arthur E ^a,c  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Diphtheria toxin; DT388IL3; Fusion toxin

Indexed keywords

CEFTAZIDIME; DIPHTHERIA TOXIN; INTERLEUKIN 3; VANCOMYCIN; DIPHTHERIA TOXIN INTERLEUKIN 3 FUSION PROTEIN, RECOMBINANT; DIPHTHERIA TOXIN-INTERLEUKIN-3 FUSION PROTEIN, RECOMBINANT; HYBRID PROTEIN; INTERLEUKIN 3 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; AUTOPSY; BLOOD ANALYSIS; BONE MARROW BIOPSY; BONE MARROW CELL; CATALYSIS; CELL HYPERPLASIA; CONTROLLED STUDY; CROSS REACTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; HISTOPATHOLOGY; IMMUNOTOXICITY; MALAISE; MALE; MONKEY; NONHUMAN; ORGAN INJURY; PLASMA HALF LIFE; PRIORITY JOURNAL; TOXICITY TESTING; VASCULAR TISSUE; VASCULITIS; ANIMAL; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; HALF LIFE TIME; HUMAN; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MACACA; MAXIMUM TOLERATED DOSE; METABOLISM;

ANIMALS; ANOREXIA; BONE MARROW CELLS; DIPHTHERIA TOXIN; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-3; MACACA FASCICULARIS; MALE; MAXIMUM TOLERATED DOSE; RECEPTORS, INTERLEUKIN-3; RECOMBINANT FUSION PROTEINS; VASCULITIS;

EID: 3042813426     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190410001663572     Document Type: Article

References (31)

1. Schiffer, C.A. (2001) "Acute myeloid leukemia in adults: where do we go from here?", Cancer Chemother. Pharmacol., 48(Suppl. 1), S45-S52.
2. Burnett, A.K. (2001) "Evaluating the contribution of allogeneic and autologous transplantation to the management of acute myeloid leukemia in adults", Cancer Chemother. Pharmacol., 48(Suppl. 1), S53-S58.
3. Choe, S., Bennett, M.J., Fujii, G., Curmi, P.M.G., Kantardjieff, K.A., Collier, R.J., et al. (1992) "The crystal structure of diphtheria toxin", Nature, 357, 216-222.
4. Brooke, J.S. and Cha, J.H. (2000) "Molecular characterization of key diphtheria toxin: receptor interactions", Biochem. Biophys. Res. Commun., 275, 374-381.
5. Silverman, J.A., Mindell, J.A., Finkelstein, A., Shen, W.H. and Collier, R.J. (1994) "Mutational analysis of the helical hairpin region of diphtheria toxin transmembrane domain", J. Biol. Chem., 269, 22524-22532.
6. Bodley, J.W., Dunlop, P.C. and Van Ness, B.G. (1984) "Diphthamide in elongation factor 2: ADP ribosylation, purification, and properties", Meth. Enzymol., 106, 378-387.
7. vanderSpek, J.C. and Murphy, J.R. (2000) "Fusion protein toxins based on diphtheria toxin: selective targeting of growth factor receptors of eukaryotic cells", Meth Enzymol, 327, 239-249.
8. Frankel, A.E., Ramage, J., Latimer, A., Feely, T., Delatte, S., Hall, P., et al. (1999) "High level synthesis and maximal purification of the recombinant diphtheria fusion toxin DTGM for phase I clinical trials", Prot. Exp. Purif., 16, 190-201.
9. 388GMCSF) for refractory or relapsed acute myeloid leukemia (AML)", Clin. Cancer Res., 8, 1004-1013.
10. Frankel, A.E., Ramage, J., Gannaway, S., Kiser, M., Alexander, R., Kucera, G., et al. (2000) "Characterization of diphtheria fusion toxins targeted to the interleukin-3 receptor", Prot. Eng., 13, 575-581.
11. Frankel, A.E., McCubrey, J., Miller, M.S., Delatte, S., Ramage, J., Kiser, M., et al. (2000) "Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias", Leukemia, 14, 576-585.
12. Suda, T., Suda, J., Ogawa, M. and Ihle, J.N. (1985) Permissive role of interleukin 3 (IL-3) in proliferation and differentiation of multipotential hematopoietic progenitors in culture", J. Cell. Physiol., 124, 182-190.
13. Ailles, L.E., Gerhard, B. and Hogge, D.E. (1997) "Detection and characterization of primitive malignant and normal prgenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines", Blood, 90, 2555-2564.
14. Alexander, R.L., Ramage, J., Kucera, G.L., Caliguiri, M.A. and Frankel, A.E. (2001) "High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia (AML) correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein", Leuk. Res., 25, 875-881.
15. Alexander, R.L., Kucera, G.L., Klein, B. and Frankel, A.E. (2000) "In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL3 fusion protein", Bioconj. Chem., 11, 564-568.
16. Feuring-Buske, M., Frankel, A.E., Alexander, R.L., Gerhard, B. and Hogge, D.E. (2002) "A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors", Cancer Research, 62, 1730-1736.
17. 388IL3) prolongs disease-free survival of leukemic immunocompromised mice", Leukemia, 17, 155-159.
18. Uckun, F.M., Yanishevski, Y., Turner, N., Waurzyniak, B., Messinger, Y., Chelstrom, L.M., et al. (1997) "Pharmacokinetic features, immuongenecity, and toxicity of B43(anti-CD19)-pokeweed anitiviral protein immunotoxin in cynomolgus monkeys", Clin. Cancer Res., 3, 325-337.
19. Hotchkiss, C.E., Hall, P.D., Cline, J.M., Willingham, M.C., Kreitman, R.J., Gardin, J., et al. (1999) "Toxicology and Pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony stimulating factor (GMCSF) in cynomolgus monkeys", Toxicol. Appl. Pharmacol., 158, 152-160.
20. Hall, P.D., Virella, G., Willoughby, T., Atchley, D.H., Kreitman, R.J. and Frankel, A.E. (2001) "Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia", Clin. Immunol., 100(2), 191-197.
21. van Gils, F.C., Budel, L.M., Burger, H., van Leen, R.W., Lowenberg, B. and Wagemaker, G. (1994) "Interleukin -3 (IL-3) receptors on rhesus monkey bone marrow cells: species specificity of human IL-3, binding characteristics, and lack of competition with GM-CSF", Exp. Hematol., 22, 248-255.
22. Van Gils, F.C., Mulder, A.H., van den Bos, C., Burger, H., van Leen, R.W. and Wagemaker, G. (1993) "Acute side effects of homologous interleukin-3 in rhesus monkeys", Am. J. Pathol., 143, 1621-1633.
23. Kiser, M., McCubrey, J.A., Steelman, L.S., Shelton, J.G., Ramage, J., Alexander, R.L., et al.. (2001) "Oncogene-dependent engraftment of human myeloid leukemia cells in immunosup-pressed mice", Leukemia, 15, 814-818.
24. 389EGF fusion protein therapy of refractory glioblastoma multiforme", Curr. Pharm. Biotech., 4, 39-49.
25. US Food and Drug Administration (2003) Product Approval Information-Licensing Action. www.fda.gov/cber/review/denser 020599rl.pdf.
26. Wu, A., Yamada, K., Neville, D.M., Awwad, M., Wain, J.C., Shimizu, A., et al. (2003) "Xenogeneic thymus transplantation in a pig-to-baboon model", Transplantation, 75, 282-291.
27. Mayer, P., Valent, P., Schmidt, G., Liehl, E. and Bettelheim, P. (1989) "The in vivo effects of recombinant human interleukin-3: demonstrating basophil differentiation factor, histamine-producing activity, and priming of GM-CSF-responsive progenitors in nonhuman primates", Blood, 74, 613-621.
28. 390-mIL-3 fusion immunotoxin: ex vivo and in vivo studies in mice", Protein Engineering, 12, 779-785.
29. Korpelainen, E.I., Gamble, J.R., Smith, W.B., Goodall, G.J., Qiyu, S., Woodcock, J.M., et al. (1993) "The receptor for interleukin 3 is selectively induced in human endothelial cells by tumor necrosis factor α and potentiates interleukin 8 secretion and neutrophil transmigration", Proc. Natl. Acad. Sci. USA, 90, 11137-11141.
30. Dentelli, P., Del Sorbo, L., Rosso, A., Molinar, A., Garbarino, G., Camussi, G., et al. (1999) "Human IL-3 stimulates endothelial cell motility and promotes in vivo new vessel formation" , J. Immunol., 163, 2151-2159.
31. Tomblyn, M.R. and Tallman, M.S. (2003) "New developments in antibody therapy for acute myeloid leukemia", Semin. Oncol., 30, 502-508.